Penpulimab

Penpulimab is a cancer medicine for a type of cancer in the upper part of the throat behind the nose. It's given as an infusion into a vein. It works by helping the body's immune system find and attack cancer cells.

Medication

What people taking Penpulimab report

Every report comes from a Lived member, sent anonymously.

Have you tried Penpulimab for Nasopharyngeal Cancer?

NameHow it went

About Penpulimab

What It's For

Penpulimab (official US name penpulimab-kcqx) is an immunotherapy medicine for adults with nasopharyngeal carcinoma, a cancer that starts in the nasopharynx, the upper part of the throat behind the nose. The US Food and Drug Administration approved it in 2025 for the non-keratinizing type of this cancer. It has no separate brand name in the US. It has two approved uses. For cancer that has come back after earlier treatment (recurrent) or has spread to other parts of the body (metastatic), it can be the first treatment for that stage, given together with the chemotherapy medicines gemcitabine plus either cisplatin or carboplatin. It can also be used on its own when the cancer has spread and kept growing despite platinum-based chemotherapy and at least one other treatment.

How It Works

Immune cells called T cells can recognize and destroy cancer cells, but they carry a built-in brake called PD-1 (programmed death receptor-1). When PD-1 is switched on, the T cell holds back. Some tumors exploit this by producing large amounts of the proteins that switch PD-1 on, which helps them hide from the immune system. Penpulimab is a laboratory-made antibody that attaches to PD-1 and blocks that signal, so T cells can keep attacking the tumor. It belongs to the same family of medicines as other PD-1 checkpoint inhibitors. Because it releases a general brake on the immune system rather than targeting only cancer, it can also lead the immune system to attack healthy organs, which explains its most important side effects.

Dosage & Administration

Penpulimab is given in a clinic or infusion center as an infusion into a vein that takes about 60 minutes. With chemotherapy, it is given every 3 weeks: penpulimab first, then gemcitabine, then cisplatin or carboplatin, for six cycles, after which penpulimab continues alone every 3 weeks. When used on its own, it is given every 2 weeks. Treatment continues until the cancer grows, side effects become unacceptable, or a maximum of 24 months is reached. The dose is not lowered for side effects. Instead, the oncology team pauses or permanently stops treatment depending on the type and severity of the problem. If an infusion appointment is missed, call to reschedule as soon as possible.

Side Effects

When penpulimab is combined with chemotherapy, the most common side effects are nausea, vomiting, constipation, loss of appetite and weight, tiredness, cough, rash and fever, many of which come largely from the chemotherapy. Low blood counts are also common with the combination. Used alone, the most common problems are anemia (low red blood cell count) and an underactive thyroid. An underactive thyroid is common in both settings, affecting almost half of people in the combination trial, and it is usually managed with thyroid hormone replacement. The most important risk is that the immune system can attack healthy organs. This can affect the lungs, bowel, liver, kidneys, skin and hormone glands, and it can be serious or, rarely, fatal. It can start at any point, including after the last dose. Contact the care team right away for a new or worsening cough, shortness of breath or chest pain; diarrhea, black or bloody stools, or severe belly pain; yellowing of the skin or eyes, dark urine, or easy bruising; headaches that won't go away, extreme tiredness, dizziness or fainting, or unusual hunger or thirst; less urine or swollen ankles; or skin blistering, peeling or painful mouth sores. Caught early, these reactions are usually treated with corticosteroids or hormone replacement, and treatment may be paused. Infusion reactions can occur during or soon after a dose. Tell the infusion staff straight away about chills or shaking, flushing, itching, wheezing or shortness of breath, back pain, or feeling faint.

Interactions & Warnings

Before starting, tell the oncology team about any autoimmune condition such as Crohn's disease, ulcerative colitis or lupus, any organ transplant (including a cornea transplant), a past or planned stem cell transplant from a donor, previous radiation to the chest, or a nervous system condition such as myasthenia gravis. Unleashing the immune system can flare these conditions, trigger transplant rejection, or cause serious complications such as graft-versus-host disease after a donor stem cell transplant. The main trials excluded people with most autoimmune diseases and people who needed immune-suppressing medicine, so less is known about how it behaves in those groups. Penpulimab can harm a developing baby. People who can become pregnant need a pregnancy test before starting and should use effective birth control during treatment and for 4 months after the last dose. Breastfeeding is not recommended during treatment or for 4 months afterward. The label lists no specific drug interactions, but the care team should still know about every prescription, over-the-counter medicine and supplement, especially anything that affects the immune system, such as steroids.

What to Expect

Treatment is a regular routine of clinic visits for infusions, with blood tests before and during treatment to check liver and kidney function, thyroid hormone levels and, with chemotherapy, blood counts. Scans are repeated every couple of months to see whether the cancer is shrinking, stable or growing. The benefit varies widely. In the main trial of first treatment for recurrent or metastatic disease, adding penpulimab to chemotherapy lengthened the typical time before the cancer started growing again from about 7 months to about 9.6 months. Whether it also helps people live longer was not yet known when it was approved. When used alone after other treatments had failed, the tumor shrank in about 28 out of 100 people, and almost half of those responses lasted at least a year. Almost everyone in these trials was of Asian background, so results in other populations are less certain. Some side effects, especially thyroid problems, can be lasting and may need ongoing treatment even after penpulimab ends. Because immune reactions can appear weeks or months later, keep reporting new symptoms after the last infusion and mention past penpulimab treatment to any new doctor.

Questions to Ask Your Doctor

  1. 1.Why is penpulimab a good option for my cancer, and how does it compare with other immunotherapy or chemotherapy choices?
  2. 2.How will we know whether it is working, and how often will I have scans and blood tests?
  3. 3.Which symptoms should make me call right away, and how do I reach the team after hours?
  4. 4.Do any of my other health conditions, such as an autoimmune disease or a transplant, make it riskier for me?
  5. 5.If I have a serious side effect or reach 24 months, what happens next?

Last reviewed • Oct 2026

Educational content, not medical advice.